Interview about the licensing of CD37CAR to CellPoint (in Norwegian)

CD37CAR was licensed out to CellPoint, a dutch biotech designing an "unconventional" CAR-T cell treatment for all patients. You can find the articles here and here, an English translation will soon be available.

Two inventors:

The cocoon:

 

 

 

 

In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by Else Marit Inderberg and Sébastien Wälchli’s research group at the Radium Hospital, Oslo University Hospital. ‘Clinical studies will start within a year,’ says Tol Trimborn, the founder and managing director of CellPoint.

-> Full interview in English can be found here

 
Page visits: 246